Andamertinib vs Asandeutertinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Andamertinib
Marketed by Avistone Biotechnology
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT07336732 (registry estimate)
No aligned efficacy figure on record for this race.
Asandeutertinib
Marketed by TYK Medicines, Inc.
NCT05146219 · Phase 2 · completed
The study treated 29 participants in a single arm without randomization, blinding, or a control group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT06672068 (registry estimate)
Reported efficacy
Intracranial Overall Response Rate (iORR) (13 months.); Extracranial Overall Response Rate (eORR) (13 months.): Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months (not_applicable)
Result source: NCT05146219
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Andamertinib | Asandeutertinib |
|---|---|---|
| PFS, median | —Trial running · NCT06970782 | —Trial running · NCT05382728 |
| OS, median | —Trial running · NCT06970782 | —Trial running · NCT05382728 |
| ORR | —Trial running · NCT06970782 | —Trial running · NCT05382728 |
| Duration of response, median | —Trial running · NCT06970782 | —Trial running · NCT05382728 |
PFS, median
- Andamertinib
- —Trial running · NCT06970782
- Asandeutertinib
- —Trial running · NCT05382728
OS, median
- Andamertinib
- —Trial running · NCT06970782
- Asandeutertinib
- —Trial running · NCT05382728
ORR
- Andamertinib
- —Trial running · NCT06970782
- Asandeutertinib
- —Trial running · NCT05382728
Duration of response, median
- Andamertinib
- —Trial running · NCT06970782
- Asandeutertinib
- —Trial running · NCT05382728
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Andamertinib: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Andamertinib's landscape · Asandeutertinib's landscape